Evidence map›Paper›PMID 35846421›Full record

ArticleNuclear medicine and molecular imaging2022

Technetium 99m PSMA Superscan Mimicking a Bone Scan Gone Wrong.

Evbuomwan Osayande, Fourie Carika, Engelbrecht Gerrit

Abstract read
In one paragraph

Article in Nuclear medicine and molecular imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Nuclear medicine and molecular imaging · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Evbuomwan OsayandeDepartment of Nuclear Medicine, University of The Free State, Bloemfontein, South Africa.
Fourie CarikaDepartment of Radiation Oncology, University of The Free State, Bloemfontein, South Africa.
Engelbrecht GerritDepartment of Nuclear Medicine, University of The Free State, Bloemfontein, South Africa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Imaging of metastatic castrate-resistant prostate cancer to select patients suitable for peptide receptor radioligand therapy can be performed with both SPECT and PET PSMA radiotracers. Although PET radiotracers generally have higher sensitivity and spatial resolution, SPECT tracers can be an effective alternative when PET/CT systems are unavailable in the clinical setting. We present a case of a 43-year-old male, who was referred to our facility for workup for radioligand PSMA therapy. His Tc-99m PSMA images revealed diffuse bone infiltration in a pattern mimicking a bone scan.

Indexed as

PET/CTProstate cancerSPECT/CTTc-99m PSMA

Identifiers

PMID35846421
PMCPMC9276881

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.